Access this content to learn more about the latest long-term outcomes data for larotrectinib and new perspectives on diagnostic techniques being used to identify NTRK fusion positive cancers.


Hi my name is Fernando Santini, I’m a medical oncologist at Memorial Sloan Kettering Cancer Center.

I’m here on behalf of NTRK CONNECT to present you the Highlights By selection of abstracts at AACR, ELCC and USCAP.

First, regarding the efficacy of the first-generation TRK inhibitors, it was presented the long-term follow-up of the first primary analysis of the first 55 patients treated with larotrectinib which is the first in class, highly selective and CNS active, first-generation TRK inhibitor.

It was presented the long-term efficacy data, the two-year follow-up, that showed a continuing durable and robust response with the same overall response rate of 80 percent. But equally important than the overall response rate is the durability of response with a median 35.2 outstanding months. There were no new and unexpected adverse events observed with this longer follow-up.

Moving forward from the overall population, it was also presented data from the long-term follow-up of the 14 lung cancer patients which showed the same very good overall response rate regardless of the CNS status of these patients and after progression 3 of 4 of these patients, they showed NTRK solvent front mutations as the main mechanism of resistance.

Shifting gears a little bit to the diagnostic space which can be sometimes complicated. We have several already published algorithms to detect NTRK fusions.

Starting with a very nice work presented regarding the ctDNA analysis. We need to take into consideration that the yield to detect fusions in the bloods is much lower than in the tissue, but probably a new fusion caller, an NTRK1 fusion caller algorithm improved the detection rate of NTRK1 fusion in plasma.

About the pan-TRK IHC, which can be used as like a screening method for tumours with low frequency of NTRK fusions, there is like an overall very good agreement from the pathologists from 8 different centers but we still have the caveat of not having a good cut-off of positivity.

So in summary larotrectinib continued to show a robust and durable response. After the progression it’s important to test for the mechanisms of resistance because we have now the availability of the next-generation TRK inhibitor and we really should test all the patients for NTRK fusions in order to benefit them for receiving the first-generation TRK inhibitors.

I really encourage you to access our website and download the slides and really thank you for attention.

This programme is supported by an Independent Educational Grant from Bayer

Dr Fernando Santini has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, BMS, Lilly, MDHealth, MSD, Novartis and Roche. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from AstraZeneca, Amoy Diagnostics and Bayer.

Meet the experts

Other programmes of interest

Video
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.